Second generation anti-androgens and androgen deprivation therapy with radiation therapy in the definitive management of high-risk prostate cancer.

ABSTRACT:

Background

Evolving data suggest that men with high-risk localized prostate cancer may benefit from more potent androgen receptor inhibition in the context of curative intent radiotherapy. Recently updated American Society for Clinical Oncology (ASCO) evidence-based guidelines and the National Comprehensive Cancer Network (NCCN) Guidelines have updated recommendations for the consideration of adding second generation anti-androgens to androgen deprivation therapy (ADT) in men receiving radiation therapy (RT) for noncastrate locally advanced high and very high risk nonmetastatic or node positive prostate cancer.

Methods and results

We conducted a comprehensive review of existing published and abstract presented evidence behind RT with ADT for the definitive management of high

SUBMITTER: Wang EC 

PROVIDER: S-EPMC10033329 | biostudies-literature | 2023 Mar

REPOSITORIES: biostudies-literature